Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI310, Sintilimab, and Bevacizumab in Resectable Hepatocellular Carcinoma
NCT07714317Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jul 2026
- Primary completion
- Jul 2027
01
Overview
Phase 2, randomised, open-label trial of IBI310 in hepatocellular carcinoma (HCC) (3 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Average depth of pathological response at 6 months. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
IBI310
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07714317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07714317.